Back to Clinical Trials

Brief Title: Cretostimogene Grenadenorepvec Given in Patients With Non-Muscular Invasive Bladder Cancer, Unresponsive to BCG

A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

INTRODUCTION

  • Org Study ID: CG3002S
  • Secondary ID: N/A
  • NCT ID: NCT04452591
  • Sponsor: CG Oncology, Inc.

DESCRIPTION

This clinical trial will evaluate the activity of intravesical (IVE) administration of cretostimogene grenadenorepvec (CG0070) in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ (CIS) with or without Ta/T1 disease.

To learn more contact Joanna Horn at recruitment@cgoncology.com.

BRIEF SUMMARY

To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease

DETAILED DESCRIPTION

An open-label trial designed to evaluate CG0070 + DDM in patients with NMIBC who have failed prior BCG therapy. Single treatment arm that will enroll up to 110 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease

BCG failure is defined as a persistent or recurrent disease within 12 months of completion of adequate BCG therapy.

  • Overall Status
    Recruiting
  • Start Date
    October 27, 2020
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Non Muscular Invasive Bladder Cancer

ELIGIBILITY

Key Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

- * Have pathologically confirmed World Health Organization (WHO) grading system employed for tumor grading) high-risk NMIBC unresponsive to prior BCG therapy defined as:
Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy
* Received prior adequate BCG therapy as defined as at least one of the following ("5+2" minimum exposure):
1. At least five of six doses of an initial induction course (adequate induction) plus at least two of three doses of maintenance therapy, OR

- 2. At least five of six doses of an initial induction course (adequate induction) plus at least two of six doses of a second induction course.

- * Ineligible for radical cystectomy or refusal of radical cystectomy

- * Adequate organ function
Key Exclusion Criteria:
* Muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer

- * Has known upper tract or prostatic urethra malignancy

- * Has systemic anti-cancer therapy, including investigational agents, within 4 weeks of Baseline

- * Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant

- * Prior treatment with adenovirus-based cancer therapy

- * Clinically significant or active cardiac disease

- * Active autoimmune disease

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: James Burke, MD

Role: Principal Investigator

Affiliation: CG Oncology, Inc.

Overall Contact

Name: JoAnn Horn

Phone: 516-456-1415

Email: joann.horn@CGoncology.com

LOCATION

Facility Status Contact
Facility: Mayo Clinic Cancer Center
Phoenix, Arizona 85054
United States
Status: Recruiting Contact: Contact
Clinical Trials Office All Mayo Clinic Locations
855-776-0015

Principal Investigator
Mark Tyson, MD

Facility: Arizona Institute of Urology
Tucson, Arizona 85704
United States
Status: Recruiting Contact: Contact
Crystal Palencia

Principal Investigator
Jay Page, MD

Facility: University of California - Irvine
Irvine, California 92868
United States
Status: Recruiting Contact: Contact
Steven Bereta

Principal Investigator
Edward Uchio, MD

Facility: University of Colorado
Aurora, Colorado 80045
United States
Status: Recruiting Contact: Contact
Janet Kukreja

Facility: MedStar Hospital
Washington, District of Columbia 20010
United States
Status: Recruiting Contact: Contact
Lambros Stamatakis

Facility: Mayo Clinic - Jacksonville
Jacksonville, Florida 32224
United States
Status: Recruiting Contact: Contact
Andrew Hendrix

Principal Investigator
Timothy Lyon, MD

Facility: Moffit Cancer Center
Tampa, Florida 33612
United States
Status: Recruiting Contact: Contact
Rodger Li

Facility: Emory University
Atlanta, Georgia 30322
United States
Status: Recruiting Contact: Contact
Misaki Mason

Principal Investigator
Shreyas Joshi, MD

Facility: University of Kansas
Kansas City, Kansas 66160
United States
Status: Recruiting Contact: Principal Investigator
Eugene Lee, MD

Facility: Chesapeake Urology
Severna Park, Maryland 21076
United States
Status: Recruiting Contact: Contact
Rian Dickstein

Facility: Mayo Rochester
Rochester, Minnesota 55905
United States
Status: Recruiting Contact: Contact
Paras Shah

Facility: Mercy Medical Center
Saint Louis, Missouri 63109
United States
Status: Recruiting Contact: Contact
Gautam Agarwal

Facility: New Jersey Urology
Edison, New Jersey 08837
United States
Status: Recruiting Contact: Contact
Haleema Hameed

Principal Investigator
Joshua Wein, MD

Facility: Our Lady of Lourdes
Binghamton, New York 13905
United States
Status: Recruiting Contact: Contact
Kathleen McGinley

Facility: StonyBrook Cancer Center
Stony Brook, New York 11794-263
United States
Status: Recruiting Contact: Contact
Audrey Anderson

Principal Investigator
David Golumbos, MD

Facility: Duke University
Durham, North Carolina 27710
United States
Status: Recruiting Contact: Contact
Whitney Franz

Principal Investigator
Brant Inman, MD

Facility: Wake Forest University
Winston-Salem, North Carolina 27109
United States
Status: Recruiting Contact: Contact
Matvey Tsivian

Facility: University of Toledo
Toledo, Ohio 43614
United States
Status: Recruiting Contact: Contact
Stephanie Smiddy

Principal Investigator
Firas G Petros, MD

Facility: University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania 19104
United States
Status: Recruiting Contact: Contact
Hanna Stambakio

Principal Investigator
Thomas Guzzo, MD

Facility: Prisma Health
Greenville, South Carolina 29615
United States
Status: Recruiting Contact: Contact
Leesa Judd

Principal Investigator
Ryan Werntz, MD

Facility: Carolina Urologic Research Center
Myrtle Beach, South Carolina 29572
United States
Status: Recruiting Contact: Contact
Ryan Sutton

Principal Investigator
Neal Shore, MD

Facility: Vanderbilt University Medical Center
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: Contact
Pamela Steele

Principal Investigator
Sam Chang, MD